Idasanutlin (Generic (investigational))

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Idasanutlin is an investigational drug being studied by Hoffmann-La Roche. It is currently in Phase 1 clinical trials for colorectal cancer. This trial (NCT03555149), called Morpheus-CRC, is evaluating idasanutlin in combination with other immunotherapy drugs (like atezolizumab, bevacizumab, selicrelumab) for patients with metastatic colorectal cancer that has stopped responding to standard first- and second-line treatments. The goal of this early-phase trial is primarily to assess the safety and tolerability of these combinations, as well as to get preliminary information about their effectiveness (anti-tumor activity). It is important to remember that idasanutlin is not yet approved for treating colorectal cancer and is only available as part of clinical trials.

Mechanism of Action

Idasanutlin is being investigated as part of combination therapies in clinical trials. The specific mechanism of action for idasanutlin is being studied. It is being evaluated alongside immunotherapy agents to see if these combinations can effectively target and control metastatic colorectal cancer that has progressed after initial treatments.

Side Effects

As idasanutlin is an investigational drug in early-phase clinical trials (Phase 1) The full range of potential side effects is still being evaluated. The primary focus of the current trials is on safety and determining the maximum tolerated dose. Information about specific side effects will become clearer as the trials progress. Patients participating in these trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03555149 Phase 1
Archived
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
United States, Australia, France, South Korea, Switzerland

Quick Info

Brand NameGeneric (investigational)
CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.